Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Cholinergic Neurons: Neurotransmission01:23

Cholinergic Neurons: Neurotransmission

6.3K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
6.3K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.5K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.5K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

6.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No gold standard has been established for vasoreactivity testing in patients with coronary microvascular spasm in the real world: A future task?

Internal medicine (Tokyo, Japan)·2026
Same author

Differences in Coronary Microvascular Spasms Induced by Acetylcholine and Ergonovine.

Internal medicine (Tokyo, Japan)·2025
Same author

The Need for Separate Testing with Acetylcholine for the Assessment of Endothelial Dysfunction and Coronary Artery Spasm.

European cardiology·2024
Same author

Safety and Usefulness of Intracoronary Acetylcholine 200 μg Into the Left Coronary Artery as Vasoreactivity Testing: Comparisons With Intracoronary Acetylcholine Maximum 100 μg.

Clinical cardiology·2024
Same author

A Review of the Role of Tests of Coronary Reactivity in Clinical Practice.

European cardiology·2024
Same author

Lack of Class I Vasoreactivity Testing for Diagnosing Patients With Coronary Artery Spasm.

Clinical cardiology·2024

Related Experiment Video

Updated: Apr 7, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

17.1K

Overview of the Acetylcholine Spasm Provocation Test.

Shozo Sueda1, Hiroaki Kohno1, Takaaki Ochi2

  • 1Department of Cardiology, Ehime Niihama Prefectural Hospital, Ehime, Japan.

Clinical Cardiology
|July 16, 2015
PubMed
Summary

The acetylcholine (ACh) spasm provocation test is a safe method for diagnosing coronary artery spasm. Modifications to ACh dosage and testing protocols may improve its diagnostic accuracy for current clinical practice.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

17.1K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.5K

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Diagnostic Testing

Background:

  • The acetylcholine (ACh) spasm provocation test is a widely used method for inducing coronary spasm.
  • While safe and effective, current guidelines may require updates for optimal real-world application.
  • The test has historically been the gold standard for diagnosing variant angina.

Purpose of the Study:

  • To review the efficacy and safety of the ACh spasm provocation test over 24 years.
  • To propose modifications to the ACh test for improved diagnostic yield in contemporary cardiology.
  • To provide recommendations for the next generation of cardiologists regarding ACh testing.

Main Methods:

  • Review of clinical experience with the ACh spasm provocation test over 24 years.
  • Analysis of diagnostic success rates with varying ACh dosages (50/100 µg vs. 80/200 µg).
  • Comparison of ACh testing with ergonovine testing, particularly in specific patient populations.

Main Results:

  • The ACh test is a reliable and useful method for gathering clinical information.
  • Higher ACh doses (80/200 µg) may be beneficial in certain cases with low to moderate coronary artery disease activity.
  • Sequential testing and prioritizing ACh over ergonovine in female patients are recommended due to ACh supersensitivity.

Conclusions:

  • The ACh spasm provocation test remains a valuable diagnostic tool.
  • Revising maximal ACh dosage recommendations may enhance its utility in current practice.
  • Modified ACh testing protocols, including sequential testing and consideration of patient demographics, are recommended for future use.